About
About Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Visit company website
5 years, 4 months ago
Harpoon Therapeutics, Inc is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.0.
Harpoon Therapeutics, Inc's total revenue rose by 235.4% to $7M since the same quarter in the previous year.
Its net income has increased by 20.4% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 145.7% to $-15M since the same quarter in the previous year.
Based on the above factors, Harpoon Therapeutics, Inc gets an overall score of 3/5.